Why Jazz Pharmaceuticals plc’s (JAZZ) Stock Is Up 6.29%
As of Tuesday, November 03, Jazz Pharmaceuticals plc’s JAZZ share price has surged by 6.29%, which has investors questioning if this is right time to sell.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Commentary & Analysis
What You Need to Know About Jazz Pharmaceuticals plc's Q4 Earnings
Jazz Pharmaceuticals plc's fiscal Q4 earnings report was released on Monday, November 02. Let's dive in to see if (JAZZ) missed or beat analyst's expectations.Jenna Brashear
Why Jazz Pharmaceuticals plc’s (JAZZ) Stock Is Down 5.13%
As of Thursday, October 08, Jazz Pharmaceuticals plc’s JAZZ share price has dipped by 5.13%, which has investors questioning if this is right time to buy.Jenna Brashear
Which Is a Better Investment, AstraZeneca PLC or Jazz Pharmaceuticals plc Stock?
Learn more about whether AstraZeneca PLC or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
Which Is a Better Investment, AstraZeneca PLC or Jazz Pharmaceuticals plc Stock?
Learn more about whether AstraZeneca PLC or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Financial Summary
| Share Statistics | JAZZ | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $15,042.7 | $447.1 | 83% |
|
| Shares Out (Mil) | 64.7 | 44.5 | 54% |
|
| Institutional Ownership | 97.2% | 81.1% | 73% |
|
| Float (Mil) | 62.3 | 46.4 | 51% |
|
| Beta | 0.37 | 0.76 | 21% |
|
| Avg Daily Volume (000s) | 934 | 274 | 68% |
|
| Price Change (52-week) |
69.4% | 55.3% | 91% |
|
| Growth | JAZZ | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 12.5% | 5.7% | 67% |
|
| Net Income (5yr) | (28.4%) | (2.0%) | 15% |
|
| EPS (5yr) | (27.6%) | 14.9% | 9 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (33.4%) | (15.1%) | 16% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 15 | 16 | 17 | |
| Current EPS | $6.585 | $14.941 | $25.760 | |
| Month Ago EPS | $6.563 | $18.151 | $21.476 | |
| # Rev Up | 1 | 1 | 2 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | $6.457 | $25.031 | $25.801 | |
| Year/Year Chg | (188.0%) | (355.8%) | (558.5%) | |
| Financials | JAZZ | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $4,718 | $317 | 73% |
|
| Net Income (TTM) (Mil) | $206 | ($11) | 68% |
|
| EPS (TTM) | $3.284 | ($0.600) | 79% |
|
| Operating Cash Flow (TTM) (Mil) | $1,693 | ($6) | 86% |
|
| Net Cash Flow (TTM) (Mil) | $710 | $1 | 93% |
|
| Long-Term Debt (Q1) (Mil) | $4,613 | $6 | 84% |
|
| Enterprise Value (Q1) (Mil) | $17,702 | $458 | 82% |
|
| Valuation | JAZZ | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.58 | 2.16 | 72% |
|
| P/E | 75.6 | 18.1 | 91% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.3 | na |
|
| Ratios | JAZZ | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 91.1% | 69.4% | 94% |
|
| Net Margin | 4.4% | 3.3% | 45% |
|
| ROA | 1.8% | (22.2%) | 54% |
|
| ROE | 5.1% | (21.8%) | 44% |
|
| Liabilities to Assets | 65.1% | 31.8% | 60% |
|
| F-Score | 7 | 3 | 82% |
|
Jazz Pharmaceuticals plc did not pass any screens on 11/4/2026.
